2023 - Research.com Microbiology in United States Leader Award
2010 - Maxwell Finland Award for Scientific Achievement, National Foundation for Infectious Diseases
His primary areas of study are Intensive care medicine, Internal medicine, Surgery, Microbiology and Staphylococcus aureus. The concepts of his Intensive care medicine study are interwoven with issues in Epidemiology and Incidence. Richard P. Wenzel regularly links together related areas like Bacteremia in his Internal medicine studies.
In his study, Clinical trial and Adverse effect is inextricably linked to Placebo, which falls within the broad field of Surgery. His Microbiology research includes elements of Vancomycin and Mycosis. Richard P. Wenzel interconnects Antibiotics and Antibacterial agent in the investigation of issues within Staphylococcus aureus.
His main research concerns Intensive care medicine, Microbiology, Internal medicine, Infection control and Surgery. His studies in Intensive care medicine integrate themes in fields like Epidemiology, Antibiotics and Health care. His Microbiology research incorporates elements of Vancomycin and Staphylococcus aureus.
His Internal medicine research is multidisciplinary, incorporating elements of Bacteremia and Placebo. His Bacteremia study integrates concerns from other disciplines, such as Mortality rate and Blood culture. His Surgery research incorporates themes from Relative risk and Incidence.
Richard P. Wenzel mainly investigates Intensive care medicine, Internal medicine, Infection control, Antibiotics and Microbiology. His studies in Intensive care medicine integrate themes in fields like Methicillin-resistant Staphylococcus aureus, Clinical trial and Health care. His Internal medicine research is multidisciplinary, relying on both Bacteremia, Surgery and Hygiene.
The various areas that Richard P. Wenzel examines in his Surgery study include Mupirocin, Risk factor and Staphylococcus aureus. The study incorporates disciplines such as Vancomycin, Linezolid, Randomized controlled trial and Drug resistance in addition to Antibiotics. His studies deal with areas such as Intensive care unit and Emergency medicine as well as Intensive care.
Intensive care medicine, Antibiotics, Staphylococcus aureus, Surgery and Internal medicine are his primary areas of study. His Intensive care medicine study combines topics in areas such as Methicillin-resistant Staphylococcus aureus, Clinical trial, Health care and Public health. His Antibiotics research includes themes of Vancomycin, Randomized controlled trial, Mycosis and Number needed to treat.
Richard P. Wenzel has researched Surgery in several fields, including Mass screening, Mupirocin, Immune system and Risk factor. Septic shock, Sepsis and Retrospective cohort study are among the areas of Internal medicine where the researcher is concentrating his efforts. As a part of the same scientific family, Richard P. Wenzel mostly works in the field of Septic shock, focusing on Univariate analysis and, on occasion, Bacteremia.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study
Hilmar Wisplinghoff;Tammy Bischoff;Sandra M. Tallent;Harald Seifert.
Clinical Infectious Diseases (2004)
The Natural History of the Systemic Inflammatory Response Syndrome (SIRS): A Prospective Study
M. S. Rangel-Frausto;Didier Pittet;M. Costigan;T. Hwang.
Nosocomial Bloodstream Infections in United States Hospitals: A Three-Year Analysis
Michael B. Edmond;Sarah E. Wallace;Donna K. McClish;Michael A. Pfaller.
Clinical Infectious Diseases (1999)
Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality.
Didier Pittet;Debra Tarara;Richard P. Wenzel.
Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
Fisher Cj;Dhainaut Jf;Opal Sm;Pribble Jp.
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Sergio B. Wey;Motomi Mori;Michael A. Pfaller;Robert F. Woolson.
JAMA Internal Medicine (1988)
Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial
E Abraham;R Wunderink;H Silverman;T M Perl.
Prevention and Control of Nosocomial Infections
Richard P. Wenzel.
Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals: A Challenge to Hospital Leadership
D A Goldmann;R A Weinstein;R P Wenzel;O C Tablan.
A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis
R L Greenman;R M Schein;M A Martin;R P Wenzel.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: